KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Royalty Pharma (RPRX) Invested Capital (2019 - 2025)

Historic Invested Capital for Royalty Pharma (RPRX) over the last 7 years, with Q3 2025 value amounting to $18.6 billion.

  • Royalty Pharma's Invested Capital rose 392.23% to $18.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $18.6 billion, marking a year-over-year increase of 392.23%. This contributed to the annual value of $18.0 billion for FY2024, which is 1069.83% up from last year.
  • Latest data reveals that Royalty Pharma reported Invested Capital of $18.6 billion as of Q3 2025, which was up 392.23% from $17.5 billion recorded in Q2 2025.
  • In the past 5 years, Royalty Pharma's Invested Capital registered a high of $18.6 billion during Q3 2025, and its lowest value of $15.7 billion during Q1 2021.
  • For the 5-year period, Royalty Pharma's Invested Capital averaged around $17.1 billion, with its median value being $17.3 billion (2021).
  • Its Invested Capital has fluctuated over the past 5 years, first soared by 11860.64% in 2021, then crashed by 1033.44% in 2023.
  • Over the past 5 years, Royalty Pharma's Invested Capital (Quarter) stood at $17.3 billion in 2021, then dropped by 4.05% to $16.6 billion in 2022, then dropped by 2.54% to $16.2 billion in 2023, then grew by 10.7% to $18.0 billion in 2024, then grew by 3.41% to $18.6 billion in 2025.
  • Its last three reported values are $18.6 billion in Q3 2025, $17.5 billion for Q2 2025, and $17.4 billion during Q1 2025.